A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (NCT02726386)

🧪 Interventions in This Study

• ND0612 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (57 Sites)

Showing the first 25 of 57 sites.

• Xenoscience — Phoenix, Arizona
• Clinical Trials Inc. — Little Rock, Arkansas
• The Parkinsons and Movement Disorder Institute — Fountain Valley, California
• Neuro Pain Medical Center — Fresno, California
• University of Colorado Denver — Aurora, Colorado
• Rocky Mountain Movement Disorders Center — Englewood, Colorado
• Parkinson's Disease and Movement Disorder Center of Boca Raton — Boca Raton, Florida
• MD Clinical — Hallandale, Florida
• Infinity Clinical Research, LLC — Hollywood, Florida
• University of Florida Health at Jacksonville — Jacksonville, Florida
• Neurology Associates, PA — Maitland, Florida
• Parkinsons Disease Treatment Center of Southwest Florida — Port Charlotte, Florida
• Suncoast Neuroscience Associates — St. Petersburg, Florida
• Infinity Clinical Research, LLC — Sunrise, Florida
• USF Health Parkinson's Disease and Movement Disorders — Tampa, Florida
• Northwestern University — Chicago, Illinois
• Unity Point Health — Des Moines, Iowa
• University of Maryland, Neurology — Baltimore, Maryland
• QUEST Research Institute — Farmington Hills, Michigan
• Henry Ford Hospital — West Bloomfield, Michigan
• Pyramid Clinical Research — Somerset, New Jersey
• University of Cincinnati — Cincinnati, Ohio
• The Movement Disorder Clinic of Oklahoma — Tulsa, Oklahoma
• Synergy Trials — Richmond, Virginia
• Sentara Neuroscience Institute — Virginia Beach, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Parkinson's Disease

• Genotypic Influences on Network Progression in Parkinson's Disease — Manhasset, New York
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Phoenix, Arizona
• Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease — New Haven, Connecticut
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD — Phoenix, Arizona
• Cont. of a Study to Evaluate Implanting Peripheral Nerve Grafts Into Subjects With Parkinson's Disease (PD) During DBS — Lexington, Kentucky
• ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease — Toronto, Ontario

Explore by condition: All Parkinson's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.